Post-chemotherapy robot-assisted retroperitoneal lymph node dissection for metastatic germ cell tumors: safety and perioperative outcomes
- 28 July 2023
- journal article
- research article
- Published by Springer Nature in World Journal of Urology
- Vol. 41 (9) , 2405-2411
Abstract
Purpose To evaluate the feasibility, safety, and early oncologic outcomes after post-chemotherapy robot-assisted retroperitoneal lymph node dissection (PC-RARPLND) for metastatic germ cell tumors (mGCT). Methods We retrospectively analyzed patients from four tertiary centers who underwent PC-RARPLND for mGCT, from 2011 to 2021. Previous treatment of mGCT, intraoperative and postoperative complications, and early oncologic outcomes were assessed. Results Overall, 66 patients were included. The majority of patients had non-seminoma mTGCT (89%). Median size of retroperitoneal lymph node (RLN) before surgery was 26 mm. Templates of PC-RARPLND were left modified, right modified, and full bilateral in 56%, 27%, and 14%, respectively. Median estimated blood loss and length of stay were 50 mL [50–150] and 2 [1–3] days. Four patients (6.1%) had a vascular injury, only one with significant blood loss and conversion to open surgery (OS). Two other patients had a conversion to OS for difficulty of dissection. No patient had transfusion, most frequent complications were ileus (10.6%) and symptomatic lymphorrea (7.6%) and no complications grade IIIb or more occurred. With a median follow-up of 16 months, two patients had a relapse, all outside of the surgical template (one in the retrocrural space with reascending markers, one in lungs). Conclusion PC-RARPLND is a challenging surgery. In expert centers and for selected patients, it seemed safe and feasible, with a low morbidity. Further prospective evaluation of this procedure and long-term oncologic results are needed.Keywords
This publication has 21 references indexed in Scilit:
- ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-upAnnals of Oncology, 2018
- Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trialThe Lancet, 2018
- Adherence to National Comprehensive Cancer Network® Guidelines for Testicular CancerJournal of Urology, 2017
- Robot-assisted Laparoscopic Retroperitoneal Lymph Node Dissection for Testicular Cancer: Evolution of the TechniqueEuropean Urology, 2016
- Robotic Primary RPLND for Stage I Testicular Cancer: a Review of Indications and OutcomesCurrent Urology Reports, 2016
- External validation of the Heidenreich criteria for patient selection for unilateral or bilateral retroperitoneal lymph node dissection for post-chemotherapy residual masses of testicular cancerWorld Journal of Urology, 2014
- The Expanding Role of Partial Nephrectomy: A Critical Analysis of Indications, Results, and ComplicationsEuropean Urology, 2010
- Postchemotherapy Retroperitoneal Lymph Node Dissection in Advanced Testicular Cancer: Radical or Modified Template ResectionEuropean Urology, 2009
- Randomized Phase III Trial Comparing Retroperitoneal Lymph Node Dissection With One Course of Bleomycin and Etoposide Plus Cisplatin Chemotherapy in the Adjuvant Treatment of Clinical Stage I Nonseminomatous Testicular Germ Cell Tumors: AUO Trial AH 01/94 by the German Testicular Cancer Study GroupJournal of Clinical Oncology, 2008
- EAU Guidelines on Testicular CancerEuropean Urology, 2001